Implementing outcomes-based risk-sharing agreements: an integrative review of applications in blood cancer in the UK and beyond

References

• Rajkumar SV. Value and cost of myeloma therapy. Am Soc Clin Oncol Educ Book. 2018;38:662–666. doi: 10.1200/EDBK_200867
   PubMedGoogle Scholar
• Leighl NB, Nirmalakumar S, Ezeife DA, et al. An arm and a leg: the rising cost of cancer drugs and impact on access. Am Soc Clin Oncol Educ Book. 2021;(41):e1–e12. doi:10.1200/EDBK_100028
   PubMedGoogle Scholar
• Hou J-Z, Ye JC, Pu JJ, et al. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. J Hematol Oncol. 2021 2021 Apr 21;14(1):66. doi: 10.1186/s13045-021-01077-3
   PubMed Web of Science ®Google Scholar
• The oncology pipeline overview: recent approvals and near-term drugs. J Hematol Oncol Phram. 2021;14(4):11. https://www.ahdbonline.com/issues/2021/december-2021-vol-14-no-4/3194-the-oncology-pipeline-overview-recent-approvals-and-near-term-drugs
   Google Scholar
• Global oncology trends 2021: outlook to 2025. North Carolina, USA: IQVIA Institute for Human Data Science; 2021.
   Google Scholar
• Oortwijn W, Determann D, Schiffers K, et al. Towards integrated health technology assessment for improving decision making in selected countries. Value Health. 2017 Sep;20(8):1121–1130.
   PubMed Web of Science ®Google Scholar
• Allen N, Walker SR, Liberti L, et al. Health Technology Assessment (HTA) case studies: factors influencing divergent HTA reimbursement recommendations in Australia, Canada, England, and Scotland. Value Health. 2017 Mar;20(3):320–328.
   PubMed Web of Science ®Google Scholar
• Wang Y, Qiu T, Zhou J, et al. Which criteria are considered and how are they evaluated in health technology assessments? A review of methodological guidelines used in Western and Asian Countries. Appl Health Econ Health Policy. 2021 May;19(3):281–304.
   PubMed Web of Science ®Google Scholar
• Mullins CD, Montgomery R, Tunis S. Uncertainty in assessing value of oncology treatments. Oncology. 2010;15(S1):58–64. doi: 10.1634/theoncologist.2010-S1-58
   Google Scholar
• Jenei K, Peacock S, Burgess M, et al. Describing sources of uncertainty in cancer drug formulary priority setting across Canada. Curr Oncol. 2021;28(4):2708–2719. doi: 10.3390/curroncol28040236
   PubMed Web of Science ®Google Scholar
• Garrison LP Jr., Towse A, Briggs A, et al. Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation: report of the ispor good practices for performance-based risk-sharing arrangements task force. Value Health. 2013 Jul;16(5):703–719. doi: 10.1016/j.jval.2013.04.011
   PubMed Web of Science ®Google Scholar
• Andersson E, Svensson J, Persson U, et al. Risk sharing in managed entry agreements—A review of the Swedish experience [Review]. Health Policy. 2020;124(4):404–410. doi: 10.1016/j.healthpol.2020.02.002
   PubMed Web of Science ®Google Scholar
• Yu JS, Chin L, Oh J, et al. Performance-based risk-sharing arrangements for pharmaceutical products in the United States: A systematic review [Review]. J Managed Care Specialty Pharm. 2017;23(10):1028–1040. doi: 10.18553/jmcp.2017.23.10.1028
   PubMed Web of Science ®Google Scholar
• Zampirolli Dias C, Godman B, Gargano LP, et al. Integrative review of managed entry agreements: chances and limitations [Review]. PharmacoEconomics. 2020;38(11):1165–1185. doi: 10.1007/s40273-020-00943-1
   PubMed Web of Science ®Google Scholar
• Piatkiewicz TJ, Traulsen JM, Holm-Larsen T. Risk-sharing agreements in the EU: a systematic review of major trends [Review]. PharmacoEconomics Open. 2018;2(2):109–123. doi: 10.1007/s41669-017-0044-1
   PubMed Web of Science ®Google Scholar
• Pauwels K, Huys I, Vogler S, et al. Managed entry agreements for oncology drugs: lessons from the European experience to inform the future [Article]. Front Pharmacol. 2017;8(APR). doi: 10.3389/fphar.2017.00171
   PubMedGoogle Scholar
• Efthymiadou O, Kanavos P. Impact of managed entry agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries.BMC Health Serv Res. 2022 [2022 Aug 20];22(1):1066. doi:10.1186/s12913-022-08437-w
   PubMed Web of Science ®Google Scholar
• Zaric GS, Zaric GS. How risky is that risk sharing agreement? mean-variance tradeoffs and unintended consequences of six common risk sharing agreements. MDM Policy Pract. 2021 Jan;6(1):2381468321990404. doi: 10.1177/2381468321990404
   Google Scholar
• Global oncology trends 2019: therapeutics, clinical development and health system implications. North Carolina, USA: IQVIA Institute for Human Data Science; 2019.
   Google Scholar
• Souza MT, Silva MD, Carvalho R. Integrative review: what is it? How to do it? Einstein (São Paulo). 2010 Mar;8(1):102–106. doi: 10.1590/s1679-45082010rw1134
   PubMedGoogle Scholar
• Kim H, Godman B, Kwon HY, et al. Introduction of managed entry agreements in Korea: Problem, policy, and politics [Article]. Front Pharmacol. 2023;14. doi: 10.3389/fphar.2023.999220
   Web of Science ®Google Scholar
• Simoens S, De Groote K, Boersma C. Critical reflections on reimbursement and access of advanced therapies [Article]. Front Pharmacol. 2022;13: doi: 10.3389/fphar.2022.771966
   Web of Science ®Google Scholar
• Ádám I, Callenbach M, Németh B, et al. Outcome-based reimbursement in central-eastern Europe and Middle-East [Article]. Front Med. 2022;9. doi: 10.3389/fmed.2022.940886
   Web of Science ®Google Scholar
• Ádám I, Callenbach M, Németh B, et al. Delayed payment schemes in central-eastern europe and middle-East [Article]. Front Med. 2022;9. doi: 10.3389/fmed.2022.940371
   Web of Science ®Google Scholar
• Bohm N, Bermingham S, Grimsey Jones F, et al. The challenges of outcomes-based contract implementation for medicines in Europe. PharmacoEconomics. 2022 Jan;40(1):13–29.
   PubMed Web of Science ®Google Scholar
• Andersson E, Svensson J, Persson U, et al. Risk sharing in managed entry agreements—A review of the Swedish experience. Health Policy. 2020 Apr;124(4):404–410.
   PubMed Web of Science ®Google Scholar
• Mundy L, Trowman R, Kearney B. Improving access to high-cost technologies in the Asia region [Article]. Int J Technol Assess Health Care. 2019;35(03):168–175. doi: 10.1017/S026646231900031X
   PubMedGoogle Scholar
• Tuffaha HW, Scuffham PA. The Australian managed entry scheme: are we getting it right? [Review]. PharmacoEconomics. 2018;36(5):555–565. doi: 10.1007/s40273-018-0633-6
   PubMed Web of Science ®Google Scholar
• Robinson MF, Mihalopoulos C, Merlin T, et al. Characteristics of Managed Entry Agreements in Australia. Int J Technol Assess Health Care. 2018;34(1):46–55. doi: 10.1017/S0266462317001106
   PubMed Web of Science ®Google Scholar
• Navarria A, Drago V, Gozzo L, et al. Do the current performance-based schemes in Italy really work? “Success fee”: A novel measure for cost-containment of drug expenditure [Article]. Value Health. 2015;18(1):131–136. doi: 10.1016/j.jval.2014.09.007
   PubMed Web of Science ®Google Scholar
• Claxton K, Palmer S, Longworth L, et al. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development [Review]. Health Technol Assess. 2012;16(46):i–323. doi: 10.3310/hta16460
   PubMed Web of Science ®Google Scholar
• Trueman P, Grainger DL, Downs KE. Coverage with evidence development: Applications and issues [Review]. Int J Technol Assess Health Care. 2010;26(1):79–85. doi: 10.1017/S0266462309990882
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Sullivan SD, Garrison, LP, et al. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010;96(3):179–190. doi: 10.1016/j.healthpol.2010.02.005
   PubMed Web of Science ®Google Scholar
• National Insitute for Health and Care Excellence. Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies. London (UK): National Institute for Health and Care Excellence; 2019.
   Google Scholar
• National Insitute for Health and Care Excellence. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies. London (UK): National Institute for Health and Care Excellence; 2019.
   Google Scholar
• National Insitute for Health and Care Excellence. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma. London (UK): National Institute for Health and Care Excellence; 2018.
   Google Scholar
• National Insitute for Health and Care Excellence. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia. London (UK): National Institute for Health and Care Excellence; 2020.
   Google Scholar
• National Insitute for Health and Care Excellence. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. London (UK): National Institute for Health and Care Excellence; 2018.
   Google Scholar
• National Insitute for Health and Care Excellence. Venetoclax for treating chronic lymphocytic leukaemia. London (UK): National Institute for Health and Care Excellence; 2017.
   Google Scholar
• National Insitute for Health and Care Excellence. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma. London (UK): National Institute for Health and Care Excellence; 2020.
   Google Scholar
• National Insitute for Health and Care Excellence. Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma. London (UK): National Institute for Health and Care Excellence; 2019.
   Google Scholar
• National Insitute for Health and Care Excellence. Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. London (UK): National Institute for Health and Care Excellence; 2018.
   Google Scholar
• National Insitute for Health and Care Excellence. Bortezomib monotherapy for relapsed multiple myeloma. London (UK): National Institute for Health and Care Excellence; 2007.
   Google Scholar
• Kang J, Cairns J. “Don’t think twice, It’s all right”: using additional data to reduce uncertainty regarding oncologic drugs provided through managed access agreements in England.Pharmacoecon Open. 2022 [2022 Sep 20];7(1):77–91. doi:10.1007/s41669-022-00369-9
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Gries K, Sullivan SD, et al. Current status and trends in performance-based schemes between health care payers and manufacturers [Conference Abstract]. Appl Health Econ Health Policy. 2014;12(3):231–8. doi:10.1007/s40258-014-0093-x
   PubMedGoogle Scholar